Who makes elotuzumab?

Elotuzumab is a humanised IgG1 immunostimulatory monoclonal antibody that binds to the cell surface glycoprotein CS1 (also known as CD319, CD2 subset 1 or SLAMF7), being developed by Bristol-Myers Squibb (BMS) and AbbVie, for the treatment of multiple myeloma.

Is elotuzumab anti CD38?

Since daratumumab and elotuzumab have different mechanisms of action, one targeting CD38 and the other SLAMF7, combination treatment with elotuzumab could be likewise an option treatment for anti-CD38 refractory RRMM.

Is elotuzumab a monoclonal antibody?

Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor, expressed on normal and malignant plasma cells with a lower expression on other lymphoid cells such as natural killer (NK) cells.

Who owns Empliciti?

Bristol Myers Squibb Reports Primary Results of ELOQUENT-1 Study Evaluating Empliciti (elotuzumab) Plus Revlimid (lenalidomide) and Dexamethasone in Patients with Newly Diagnosed, Untreated Multiple Myeloma.

How is Isatuximab administered?

Isatuximab is given as an infusion into a vein. A healthcare provider will give you this injection. You will be watched closely for at least 30 minutes after your first 2 infusions to make sure you do not have an allergic reaction. Isatuximab is given in a 28-day treatment cycle.

Does Daratumumab cause immunosuppression?

“Daratumumab promotes T-cell expansion and activation, depletes immunosuppressive regulatory cells, and has multiple different mechanisms of action.” However, daratumumab is not the only immunomodulatory agent under investigation in multiple myeloma.

What is Daratumumab made of?

Daratumumab is an immunoglobulin G1 kappa (IgG1k) human mAb that binds to a unique CD38 epitope on CD38-expressing cells with high affinity and was developed by the immunization of human immunoglobulin transgenic mice with recombinant CD38 protein [16]. de Weers et al.

Is isatuximab a chemotherapy drug?

Drug Type: Isatuximab is an anti-cancer (“antineoplastic” or “cytotoxic”) drug. This medication is a monoclonal antibody directed against CD38, a molecule present on myeloma cells (for more detail, see “How Isatuximab Works” below).

Is daratumumab an immunotherapy or chemo?

Darzalex isn’t chemotherapy. It’s a type of biologic treatment and is sometimes called targeted therapy or immunotherapy. This means that Darzalex is designed to work with your immune system (your body’s defense against infection).

Who owns DARZALEX?

company announcement No. 39 of September 22, 2020. DARZALEX® (daratumumab) is the first monoclonal antibody (mAb) to receive U.S. Food and Drug Administration approval to treat multiple myeloma and has become a backbone therapy in the treatment of this disease. Daratumumab is being developed by Janssen Biotech, Inc.

What is the best treatment for multiple myeloma?

Steroids. Corticosteroids help destroy myeloma cells and make chemotherapy more effective. The most common types used to treat myeloma are dexamethasone and prednisolone. Steroids are taken by mouth after eating.

Who makes Isatuximab?

Sanofi-Aventis
Names. Isatuximab is the United States Adopted Name (USAN). It was developed by ImmunoGen and Sanofi-Aventis with the development name SAR-650984.